The transmembrane 6 superfamily member 2 (TM6SF2) gene E167K variant (rs58542926) was identified by exome-wide association study as a nonsynonymous single nucleotide polymorphism associated with nonalcoholic fatty liver disease. The TM6SF2 E167K variant features a C-to-T substitution at nucleotide 499, encoding a glutamate with lysine change at codon 167 (E167K). TM6SF2 is markedly expressed in the liver, small intestine and kidney, and has been proposed as an important risk factor for diseases associated with lipid metabolism. Subsequently, multifunctional studies of the TM6SF2 E167K variant have been carried out in a spectrum of liver diseases, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, cirrhosis, and viral hepatitis. This review summarizes the research status of the TM6SF2 E167K variant in different liver diseases and specific populations, and discusses the potential mechanisms of the TM6SF2 E167K variant's role in the progression of various liver diseases. Citation of this article: Zhang X, Liu S, Dong Q, Xin Y, Xuan S. The genetics of clinical liver diseases: Insight into the TM6SF2 E167K variant.
Introduction
In recent years, genome-wide association studies (as an accurate tool) have been used to identify the important single nucleotide polymorphisms that are related to lipid metabolism diseases. [1] [2] [3] [4] [5] [6] The patatin-like phospholipase domain-containing 3 (PNPLA3) gene rs738409 is a well-known nonsynonymous single nucleotide polymorphism that has been identified in patients with nonalcoholic fatty liver disease (NAFLD) . Many subsequent studies have demonstrated that this PNPLA3 variant is associated with simple steatosis, severe hepatic fibrosis, cirrhosis and NAFLD-related hepatocellular carcinoma (HCC). [7] [8] [9] [10] [11] In 2014, Kozlitina et al. 12 revealed, for the first time, that the transmembrane 6 superfamily member 2 (TM6SF2) gene E167K variant (rs58542926) is another nonsynonymous single nucleotide polymorphism associated with NAFLD, by their conduct of a exome-wide association study. The TM6SF2 E167K variant was also characterized in that study as the substitution of guanine by adenine at nucleotide 499, which results in the change of glutamate to lysine at codon 167 (E167K). Human TM6SF2 is located on chromosome 19 and encodes a protein composed of 351 amino acids. 13 Protein domain prediction has revealed that TM6SF2 contains 10 transmembrane domains. 14 Expression pattern analysis has shown that TM6SF2 is mainly expressed in the kidney, small intestine and liver, all of which are tightly associated with lipid metabolism; the expression levels of TM6SF2 are relative lower in most other tissues. 12 Subcellular location analysis has shown that the TM6SF2 is predominantly expressed in the intermediate compartment of the endoplasmic reticulum and endoplasmic reticulum-Golgi intermediate in HepG2 cell lines. 15 Kozlitina et al. 12 demonstrated that TM6SF2 is an endoplasmic reticulum membrane protein, and that the E167K variant leads to misfolding and increases the degradation of TM6SF2 in cells. The secretion of Toll-like receptors from and hepatic lipid droplet content in hepatoma HepG2 cell lines are influenced by down-regulated TM6SF2 expression. 15 Among NAFLD patients, allele T carriers of TM6SF2 E167K have shown a significant association with the higher hepatic triglyceride (TG) content than C allele carriers.
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TM6SF2 has been proposed as the important risk factor in diseases associated with lipid metabolism. Subsequently, multifunctional studies of the TM6SF2 E167K variant have been carried out in a spectrum of liver diseases, including NAFLD, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and viral hepatitis. This review summarizes the current research of the TM6SF2 E167K variant in several clinical liver diseases and different populations (Table 1) , and discusses the underlying mechanisms of the TM6SF2 E167K variant's role in the progression of various liver diseases (Fig 1) . Abundant research on the TM6SF2 E167K variant in NAFLD patients has been reported since the variant was found. Anstee et al. 18 summarized some of the previous research findings and concluded that TM6SF2 could regulate hepatic lipid efflux, with deletion or mutation of TM6SF2 resulting in a reduced secretion of hepatic lipoprotein (very low density lipoproteins (VLDL), TG, and APOB), an increased accumulation of hepatocellular lipid droplets, and a higher TG level. Sookoian and colleagues 19 conducted a study in 226 Argentinean NAFLD patients (diagnosed by histopathological evidence), and the results showed a close association between the TM6SF2 E167K variant and the severity of hepatic steatosis (diagnosed by liver biopsy). The influence of TM6SF2 E167K variant has been found to be independent of sex, body mass index (BMI) and age, as well as the effect of the PNPLA3 I148M variant. Another study of a Finnish population found that the TM6SF2 E167K variant could increase fat content in the liver or in adipose tissue, but that the insulin sensitivity in these tissues was not decreased. 20 A study of Norwegians showed that the TM6SF2 E167K variant is associated with a slight decrease in total cholesterol levels, but has no effect on the levels of high-density lipoprotein-c and total TG. 21 Finally, Kozlitina et al. 12 showed that patients with the TM6SF2 E167K variant possess a lower level of serum TG and low-density lipoprotein-c, as compared to health controls in a large cohort study.
Many early studies of non-Asian populations observed a significant effect of the TM6SF2 E167K variant on NAFLD, in both adults and children. 22 To confirm whether this variant also increases the risk of NAFLD in Asians (particularly in East Asians), Wong et al. 23 investigated the effect of the E167K variant on a Chinese cohort of NAFLD patients; the results showed that the variant ratio of TM6SF2 was low in the Chinese population and that E167K may not cause severe liver injury in this population. Due to the lower number of subjects included in that study, the conclusion needs further investigation to be confirmed. Later, Wang et al. 24 performed a case-control study of a community-based Han Chinese population and found a significant relationship (P < 0.001) between the TM6SF2 E167K variant and the risk of NAFLD, despite there being a low variant ratio of TM6SF2. Kim et al. 25 investigated the genotype of TM6SF2 E167K and serum tyrosine levels in nondiabetic statin-naïve participants. The authors found that TM6SF2 E167K was associated with increased risk of type II diabetes, decreased liver production/secretion 27, 28 reported the observation of the E167K variant increasing the risk of hepatic steatosis in obese children, and that patients with the E167K variant show an increased susceptibility to hepatic steatosis, independent of other risk factors, including existence of the PNPLA3 I148M variant. In addition, Goffredo et al. 29 observed that the minor allele of the E167K variant increased susceptibility to hepatic steatosis and severe liver damage in obese children and adolescents. Finally, Viitasalo et al. 30 performed a cross-sectional study of 462 Caucasian children whose ages ranged from 6 to 9 years, with the aim of testifying to the relationship of the E167K variant with levels of liver enzymes and lipid profiles. The results indicated that patients with the E167K variant have a higher plasma alanine aminotransferase (ALT) level and lower plasma TG, total cholesterol and low-density lipoprotein-c level in childhood. These findings agree with the results of the previous studies in adults.
TM6SF2 E167K variant and progression of NAFLD
Accumulated studies suggest that the E167K variant is tightly related to the progression of NAFLD. In two histologically characterized cohorts encompassing steatosis, steatohepatitis, fibrosis and cirrhosis, Liu et al. 14, 16 demonstrated that the E167K variant was associated with advanced hepatic fibrosis or cirrhosis, and that the effects of E167K were independent of BMI, age, type 2 diabetes mellitus and PNPLA3 I148M presence. Simple steatosis is considered a nonprogressive liver disease, with only 10-20% of NAFLD patients progressing to NASH. 31 While NAFLD is generally regarded as a benign disease, NASH possesses the possibility to deteriorate to cirrhosis and HCC. 32 Yoon et al. 33 summarized the relationship of the E167K variant to the risk of NAFLD, concluding that the E167K variant may result in the development of NASH through regulation of the metabolism of cholesterol in hepatocytes. In 2014, Kozlitina and colleagues 12 ascertained the correlation between the TM6SF2 E167K variant and the increased serum ALT and AST levels through relevant studies in three cohorts (The Dallas Biobank and the Copenhagen study). The serum ALT and AST levels could be regarded as a potential marker of liver injury and NASH. In addition, Liu et al. 16 investigated the correlation between the E167K variant and the severity of histological NASH and NAFLD-related liver fibrosis; the results showed an independent effect of the variant and NASH and fibrosis. In 2015, Dongiovanni et al. 28 investigated 1201 patients with suspected NASH who were diagnosed by liver biopsy, and reported that the E167K variant could increase the risk of NASH and advanced fibrosis. The accumulated studies have shown a significant relationship between the E167K variant and the progression of NAFLD, but the underlying mechanism of the TM6SF2 E167K variant in the progression of NAFLD remains unclear.
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TM6SF2 E167K variant in alcoholic liver disease (ALD)
ALD is a common cause of liver-related mortality in the world, as excessive alcohol consumption is sustained and growing; ALD cases account for about 75% of alcohol-related mortality. 35, 36 ALD composes a spectrum of liver disease, ranging from steatosis, steatohepatitis and fibrosis to cirrhosis, that is similar to the progression of NAFLD. 37 Unlike NAFLD, only few studies have referred to the correlation of the E167K variant and the risk of ALD. A genome-wide association study in alcoholrelated cirrhotic European patients and subsequent studies in two independent European cohorts have shown the E167K variant to be a new risk locus for alcohol-related cirrhosis (P = 7.98310 −10 ). 38 Buch et al. 39 conducted a genomewide association study to screen the candidate genes associated with the risk of ALD; the results first showed that the E167K variant increased the risk of ALD-related cirrhosis by 1.4-fold (P = 0.022). When the influence of the E167K variant was analyzed by a multivariate analysis considering the potential confounding factors (sex, age, BMI, and type 2 diabetes mellitus), a modest role was observed in the patients with ALD-related cirrhosis.
The above-cited results have suggested that the E167K variant is a new additional risk locus for ALD-related cirrhosis, but still lack large enough numbers of studied populations to confirm the influence of the E167K variant in ALD patients. More subjects of different races should be included to validate the relationship of the E167K variant and the risk of ALD. The detailed mechanism of the E167K variant in the progressive of ALD also needs to be illuminated in the future.
TM6SF2 E167K variant in viral hepatitis
Hepatitis C is a major health problem around the world, and is the main cause of liver disease that could progress to cirrhosis and HCC. 40 Most hepatitis C virus (HCV) infections occur by blood transfusions and drug injection. 41 In 2015, Coppola et al. 42 investigated the relationship of the E167K variant and liver steatosis in patients with chronic hepatitis C, for the first time. The results showed that the liver steatosis scores in 18 E167K variant carriers were higher than in 130 patients with the TM6SF2 wild-type. A general linear model analysis was also performed in that study and the E167K variant was found to be an independent risk factor of steatosis (P = 0.0376).
Milano et al. 43 conducted a cross-sectional cohort study in 815 Italian clinical hepatitis C (CHC) patients to investigate the effect of the E167K variant on the score of steatosis, necroinflammation and fibrosis. The results showed that the TM6SF2 E167K variant was an independent risk factor of cirrhosis. After further controlling for steatosis and necroinflammation in the analysis, the TM6SF2 E167K variant was significantly associated with cirrhosis. These results suggested that the E167K variant is tightly associated with steatosis and fibrosis, as an independent risk factor impacts the liver damage in patients with CHC.
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For human immunodeficiency virus/HCV coinfected patients, Caterina et al. 44 reported that the E167K variant was an independent indicator of severe fibrosis, but the variant appeared to be independently associated with severe steatosis only for those patients without HCV-genotype 3. Furthermore, Petta et al. 45 found no obvious effect of E167K on the severity of liver damage in terms of steatosis or fibrosis, in their study of 694 Caucasian genotype 1 CHC patients. The results also showed a low prevalence of the E167K variant in the population with genotype 1 CHC.
In contrast to hepatitis C, there was few data on the role of the TM6SF2 E167K variant in chronic hepatitis B (CHB). Recently, Eslam et al. 46 carried out a detailed analysis in 3260 CHB patients, nonviral liver patients, and healthy controls. The results showed that the E167K variant promotes steatosis and abnormal lipid metabolism, in part by altering the expression of TM6SF2 and MTTP, and impacted CHC and CHB viral load to different degrees; the association of the TM6SF2 E167K variant with fibrosis in hepatitis B patients was unclear.
Undoubtedly, the E167K variant is significantly associated with viral hepatitis, influencing the severity of liver damage in patients with hepatitis B virus or HCV. The detailed mechanism of the E167K variant in the progression of viral hepatitis and the spread of viruses needs further study.
TM6SF2 E167K variant in HCC
HCC is the sixth most common cancer and the third cause of cancer-related morbidity and mortality worldwide. 47 The main risk factors of HCC include NASH, alcohol intake, ingestion of the fungal metabolite aflatoxin B1, and hepatitis B virus and HCV infections. [48] [49] [50] Increasing evidence has shown that patients with NAFLD are prone to progression to HCC, which could be affected by the PNPLA3 I148M variant without the presence of cirrhosis. 11, 51 In 2014, Liu et al. 16 were the first to report a significant association of the E167K variant with development of HCC, by their univariate analysis of a cohort of 99 consecutive Northern European Caucasian NAFLD patients with or without HCC. But, the significance disappeared when the relationship was investigated by multivariate analysis incorporated with the known risk factors, including BMI, sex, age, type 2 diabetes mellitus and presence of cirrhosis (P = 0.42). Subsequently, Falleti et al. 52 conducted a study to assess the interaction between TM6SF2 E167K and PNPLA3 I148M in the development of HCC. The results showed that the TM6SF2 E167K and PNPLA3 I148M variants were more likely to be found in patients with HCC, and the same for alcohol-related cirrhosis (P = 0.0007), but not in those with viral cirrhosis. This indicated that TM6SF2 E167K in connection with PNPLA3 I148M could be regarded as potential genetic risk factors for the progression of HCC in alcohol-related cirrhosis.
A recent research showed that the TM6SF2 E167K variant affected the cell cycle of the HCC cell line HEPA 1-6, possibly through up-regulated expression of cyclinD1, P53 and Rb, and down-regulated expression of P27. The abnormal cell cycle disordered energy metabolism, thereby promoting the progression of HCC. 53 It's certain that the E167K variant affects the development of HCC, but the detailed mechanism remains unclear. Further studies should be conducted to reveal the effects of the TM6SF2 E167K variant on the development of HCC that has progressed from alcohol-related and nonalcohol-related liver disease.
Conclusions
In summary, despite a low frequency of the minor allele being observed, the TM6SF2 E167K variant shows a significant association with steatosis, fibrosis, cirrhosis and HCC in various liver diseases of different etiologies (i.e. abnormal lipid metabolism, alcohol intake, hepatitis B virus and HCV infection). Identification of the TM6SF2 E167K variant in more liver diseases will contribute to establishment of new genetic predictors for the accurate and noninvasive diagnosis of NAFLD, ALD, viral hepatitis and HCC, and will help develop convenient methods of initiating early preventive and therapeutic strategies for liver disease in the seeming healthy population. However, there have been rare data on the role of TM6SF2 E167K in chronic hepatitis B and HCC. In addition, compared with considering TM6SF2 alone as a predictor for the clinical liver diseases, advocation for the establishment of a large well-phenotyped cohort with prospective follow-up is more significant. In the future, more liver disease-related polymorphisms should be identified to create a joint prediction system for the early diagnosis and treatment of clinical liver diseases.
